MannKind (MNKD) +16% premarket after the biotech company confirms with the FDA the design of two...

|About: MannKind Corporation (MNKD)|By:, SA News Editor

MannKind (MNKD) +16% premarket after the biotech company confirms with the FDA the design of two clinical studies that evaluate the efficacy and safety of Afrezza, an inhaled insulin drug considered crucial for the company. (PR)